Methods for mediating fibrotic response
Methods for mediating fibrotic response by modulating IL-25 signaling in fibrocytes are disclosed.
1. A method of suppressing fibrocyte proliferation, fibrocyte differentiation, or protein secretion by the fibrocyte induced by IL-25 in a subject having a condition associated with undesired fibrocyte proliferation, fibrocyte differentiation, or protein secretion by the fibrocyte comprising administering to the subject a therapeutically effective amount of an inhibitor of IL-25 signaling, wherein the inhibitor of IL-25 signaling is an antibody that specifically binds IL-25 and the condition is systemic sclerosis, nephrogenic systemic fibrosis, or graft versus host disease.
2. A method of suppressing fibrocyte proliferation, fibrocyte differentiation, or protein secretion by the fibrocyte induced by IL-25 in a subject having a condition associated with undesired fibrocyte proliferation, fibrocyte differentiation, or protein secretion by the fibrocyte comprising administering to the subject a therapeutically effective amount of an inhibitor of IL-25 signaling, wherein the inhibitor of IL-25 signaling is an antibody that specifically binds IL-25 and the condition is cancer.
3. The method of claim 2 , wherein the cancer is breast cancer, skin cancer, pancreatic cancer, or cervical cancer.
4. A method of suppressing fibrocyte proliferation, fibrocyte differentiation, or protein secretion by the fibrocyte induced by IL-25 in a subject having a condition associated with undesired fibrocyte proliferation, fibrocyte differentiation, or protein secretion by the fibrocyte comprising administering to the subject a therapeutically effective amount of an inhibitor of IL-25 signaling, wherein the inhibitor of IL-25 signaling is an antibody that specifically binds IL-25 and the condition is Crohn's disease, chronic cystitis, an autoimmune disease, rheumatoid arthritis, lyme disease, post surgery scarring, wound healing, or radiation damage.